Related references
Note: Only part of the references are listed.2-Styryl-4-aminoquinazoline derivatives as potent DNA-cleavage, p53-activation and in vivo effective anticancer agents
Xin-Wei Wei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells
Wensong Yao et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Antitumoral activity of quinoxaline derivatives: A systematic review
M. Montana et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting AKT for cancer therapy
Maryam Shariati et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
Francesca Corti et al.
CANCER TREATMENT REVIEWS (2019)
Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in vitro and in vivo
Qing-Qing Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
Fabio Barra et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Afsane Bahrami et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response
Klaudia Szymonowicz et al.
CANCERS (2018)
Isobutyl Nitrite-Mediated Synthesis of Quinoxalines through Double C-H Bond Amination of N-Aryl Enamines
Yan-Xiao Jiao et al.
ADVANCED SYNTHESIS & CATALYSIS (2018)
Difuran-substituted quinoxalines as a novel class of PI3K alpha H1047R mutant inhibitors: Synthesis, biological evaluation and structure activity relationship
Ning Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Aggregation-Induced Fluorescence Probe for Monitoring Membrane Potential Changes in Mitochondria
Jun Li et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-y1) benzenesulfonamides as PI3K/mTOR dual inhibitors
Jiankang Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors
Miao Zhan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Tandem C-N Bond Formation through Condensation and Metal-Free N-Arylation: Protocol for Synthesizing Diverse Functionalized Quinoxalines
Yan-Xiao Jiao et al.
JOURNAL OF ORGANIC CHEMISTRY (2017)
Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones
Tania R. Mielcke et al.
SCIENTIFIC REPORTS (2017)
Targeting PI3K Signaling in Combination Cancer Therapy
Elvire Pons-Tostivint et al.
TRENDS IN CANCER (2017)
The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells
R. Thijssen et al.
LEUKEMIA (2016)
Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery
Alessandra C. Pinheiro et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2016)
AKT in cancer: new molecular insights and advances in drug development
Prabhjot S. Mundi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Intracellular Ca2+ signaling and Ca2+ microdomains in the control of cell survival, apoptosis and autophagy
Rita M. L. La Rovere et al.
CELL CALCIUM (2016)
Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination
Jason S. L. Yu et al.
DEVELOPMENT (2016)
Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons
Daniel E. Beck et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Jennifer R. Brown et al.
CLINICAL CANCER RESEARCH (2015)
Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors
Xiaoqing Lv et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Design, Synthesis, and Biological Evaluation of O-2-Modified Indenoisoquinolines as Dual Topoisomerase I-Tyrosyl-DNA Phosphodiesterase I Inhibitors
Peng-Cheng Lv et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Magnolol inhibits angiogenesis by regulating ROS-mediated apoptosis and the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells
Gi Dab Kim et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors
Yan-Na Liu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2013)
Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors
Peng Wu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Discovery of novel morpholino-quinoxalines as PI3Kα inhibitors by pharmacophore-based screening
Peng Wu et al.
MEDCHEMCOMM (2012)
New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors
Chunquan Sheng et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors
Maris A. Cinelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
ROS stress in cancer cells and therapeutic implications
H Pelicano et al.
DRUG RESISTANCE UPDATES (2004)
Share Paper
